{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:47:08Z","timestamp":1787024828859,"version":"build-2736575974"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"14","funder":[{"DOI":"10.13039\/501100002850","name":"FONDECYT Postdoc","doi-asserted-by":"publisher","award":["3170434 (CN-R)"],"award-info":[{"award-number":["3170434 (CN-R)"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"FONDECYT","doi-asserted-by":"publisher","award":["1170718 (JC)"],"award-info":[{"award-number":["1170718 (JC)"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The two-domain dipeptidylcarboxypeptidase Angiotensin-I-converting enzyme (EC\n3.4.15.1; ACE) plays an important physiological role in blood pressure regulation via the reninangiotensin\nand kallikrein-kinin systems by converting angiotensin I to the potent vasoconstrictor angiotensin\nII, and by cleaving a number of other substrates including the vasodilator bradykinin and the\nanti-inflammatory peptide N-acetyl-SDKP. Therefore, the design of ACE inhibitors is within the priorities\nof modern medical sciences for treating hypertension, heart failures, myocardial infarction, and\nother related diseases. Despite the success of ACE inhibitors for the treatment of hypertension and\ncongestive heart failure, they have some adverse effects, which could be attenuated by selective domain\ninhibition. Crystal structures of both ACE domains (nACE and cACE) reported over the last decades\ncould facilitate the rational drug design of selective inhibitors. In this review, we refer to the history\nof the discovery of ACE inhibitors, which has been strongly related to the development of molecular\nmodeling methods. We stated that the design of novel selective ACE inhibitors is a challenge\nfor current researchers which requires a thorough understanding of the structure of both ACE domains\nand the help of molecular modeling methodologies. Finally, we performed a theoretical design of potential\nselective derivatives of trandolaprilat, a drug approved to treat critical conditions of hypertension,\nto illustrate how to use molecular modeling methods such as de novo design, docking, Molecular\nDynamics (MD) simulations, and free energy calculations for creating novel potential drugs with specific\ninteractions inside nACE and cACE binding sites.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1389557520666191224113830","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T06:58:29Z","timestamp":1577775509000},"page":"1436-1446","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Transforming Non-Selective Angiotensin-Converting Enzyme Inhibitors in C- and N-domain Selective Inhibitors by Using Computational Tools"],"prefix":"10.2174","volume":"20","author":[{"given":"Sergio","family":"Alfaro","sequence":"first","affiliation":[{"name":"Centro de Bioinformatica y Simulacion Molecular, Facultad de Ingenieria, Universidad de Talca, 1 Poniente No. 1141, Casilla 721, Talca, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9581-0206","authenticated-orcid":true,"given":"Carlos","family":"Navarro-Retamal","sequence":"additional","affiliation":[{"name":"Centro de Bioinformatica y Simulacion Molecular, Facultad de Ingenieria, Universidad de Talca, 1 Poniente No. 1141, Casilla 721, Talca, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0182-1444","authenticated-orcid":true,"given":"Julio","family":"Caballero","sequence":"additional","affiliation":[{"name":"Centro de Bioinformatica y Simulacion Molecular, Facultad de Ingenieria, Universidad de Talca, 1 Poniente No. 1141, Casilla 721, Talca, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev.bi.45.070176.000445","volume":"45","author":"Soffer R.L.","year":"1976","unstructured":"Soffer R.L.; Angiotensin-converting enzyme and the regulation of vasoactive peptides. Annu Rev Biochem 1976,45,73-94","journal-title":"Annu Rev Biochem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/17460441.2017.1335301","volume":"12","author":"Tamargo M.","year":"2017","unstructured":"Tamargo M.; Tamargo J.; Future drug discovery in renin-angiotensin-aldosterone system intervention. Expert Opin Drug Discov 2017,12(8),827-848","journal-title":"Expert Opin Drug Discov"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1753944716642680","volume":"10","author":"Williams B.","year":"2016","unstructured":"Williams B.; Drug discovery in renin-angiotensin system intervention: Past and future. Ther Adv Cardiovasc Dis 2016,10(3),118-125","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.05.020","author":"Mirabito Colafella K.M.","year":"2019","unstructured":"Mirabito Colafella K.M.; Bov\u00e9e D.M.; Danser A.H.J.; The reninangiotensin- aldosterone system and its therapeutic targets. Exp Eye Res 2019","journal-title":"Exp Eye Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/216762a0","volume":"216","author":"Ng K.K.","year":"1967","unstructured":"Ng K.K.; Vane J.R.; Conversion of angiotensin I to angiotensin II. Nature 1967,216(5117),762-766","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/218144a0","volume":"218","author":"Ng K.K.","year":"1968","unstructured":"Ng K.K.; Vane J.R.; Fate of angiotensin I in the circulation. Nature 1968,218(5137),144-150","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/225379a0","volume":"225","author":"Ferreira S.H.","year":"1970","unstructured":"Ferreira S.H.; Greene L.H.; Alabaster V.A.; Bakhle Y.S.; Vane J.R.; Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme. Nature 1970,225(5230),379-380","journal-title":"Nature"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/0005-2795(70)90017-6","volume":"214","author":"Yang H.Y.","year":"1970","unstructured":"Yang H.Y.; Erd\u00f6s E.G.; Levin Y.; A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970,214(2),374-376","journal-title":"Biochim Biophys Acta"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1476-5381.1965.tb02091.x","volume":"24","author":"Ferreira S.H.","year":"1965","unstructured":"Ferreira S.H.; A Bradykinin-Potentiating Factor (Bpf) present in the venom of bothrops jararaca. Br J Pharmacol Chemother 1965,24,163-169","journal-title":"Br J Pharmacol Chemother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/220919a0","volume":"220","author":"Bakhle Y.S.","year":"1968","unstructured":"Bakhle Y.S.; Conversion of angiotensin I to angiotensin II by cell free extracts of dog lung. Nature 1968,220(5170),919-921","journal-title":"Nature"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1021\/bi00815a005","volume":"9","author":"Ferreira S.H.","year":"1970","unstructured":"Ferreira S.H.; Bartelt D.C.; Greene L.J.; Isolation of bradykinin potentiating peptides from Bothrops jararaca venom. Biochemistry 1970,9(13),2583-2593","journal-title":"Biochemistry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/BF01930447","volume":"29","author":"Cushman D.W.","year":"1973","unstructured":"Cushman D.W.; Pluscec J.; Williams N.J.; Weaver E.R.; Sabo E.F.; Kocy O.; Cheung H.S.; Ondetti M.A.; Inhibition of angiotensin-coverting enzyme by analogs of peptides from Bothrops jararaca venom. Experientia 1973,29(8),1032-1035","journal-title":"Experientia"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1126\/science.191908","volume":"196","author":"Ondetti M.A.","year":"1977","unstructured":"Ondetti M.A.; Rubin B.; Cushman D.W.; Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977,196(4288),441-444","journal-title":"Science"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1021\/bi00644a014","volume":"16","author":"Cushman D.W.","year":"1977","unstructured":"Cushman D.W.; Cheung H.S.; Sabo E.F.; Ondetti M.A.; Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 1977,16(25),5484-5491","journal-title":"Biochemistry"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0008-6363(95)00006-2","volume":"30","author":"Opie L.H.","year":"1995","unstructured":"Opie L.H.; Kowolik H.; The discovery of captopril: From large animals to small molecules. Cardiovasc Res 1995,30(1),18-25","journal-title":"Cardiovasc Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1365-2125.1982.tb01991.x","volume":"14","author":"Ulm E.H.","year":"1982","unstructured":"Ulm E.H.; Hichens M.; Gomez H.J.; Till A.E.; Hand E.; Vassil T.C.; Biollaz J.; Brunner H.R.; Schelling J.L.; Enalapril maleate and a lysine analogue (MK-521): Disposition in man. Br J Clin Pharmacol 1982,14(3),357-362","journal-title":"Br J Clin Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2165\/00003088-200241030-00005","volume":"41","author":"Song J.C.","year":"2002","unstructured":"Song J.C.; White C.M.; Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: An update. Clin Pharmacokinet 2002,41(3),207-224","journal-title":"Clin Pharmacokinet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1592\/phco.22.1.27.33502","volume":"22","author":"Nathisuwan S.","year":"2002","unstructured":"Nathisuwan S.; Talbert R.L.; A review of vasopeptidase inhibitors: A new modality in the treatment of hypertension and chronic heart failure. Pharmacotherapy 2002,22(1),27-42","journal-title":"Pharmacotherapy"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(97)09137-X","volume":"351","author":"Nussberger J.","year":"1998","unstructured":"Nussberger J.; Cugno M.; Amstutz C.; Cicardi M.; Pellacani A.; Agostoni A.; Plasma bradykinin in angio-oedema. Lancet 1998,351(9117),1693-1697","journal-title":"Lancet"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.112.006809","volume":"65","author":"Bernstein K.E.","year":"2012","unstructured":"Bernstein K.E.; Ong F.S.; Blackwell W-L.B.; Shah K.H.; Giani J.F.; Gonzalez-Villalobos R.A.; Shen X.Z.; Fuchs S.; Touyz R.M.; A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 2012,65(1),1-46","journal-title":"Pharmacol Rev"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.107.097865","volume":"51","author":"Fuchs S.","year":"2008","unstructured":"Fuchs S.; Xiao H.D.; Hubert C.; Michaud A.; Campbell D.J.; Adams J.W.; Capecchi M.R.; Corvol P.; Bernstein K.E.; Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 2008,51(2),267-274","journal-title":"Hypertension"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.phrs.2018.07.006","volume":"134","author":"Kumar N.","year":"2018","unstructured":"Kumar N.; Yin C.; The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases. Pharmacol Res 2018,134,268-279","journal-title":"Pharmacol Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.coph.2010.11.001","volume":"11","author":"Bernstein K.E.","year":"2011","unstructured":"Bernstein K.E.; Shen X.Z.; Gonzalez-Villalobos R.A.; Billet S.; Okwan-Duodu D.; Ong F.S.; Fuchs S.; Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 2011,11(2),105-111","journal-title":"Curr Opin Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","volume":"356","author":"Messerli F.H.","year":"2000","unstructured":"Messerli F.H.; Nussberger J.; Vasopeptidase inhibition and angio-oedema. Lancet 2000,356(9230),608-609","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.1021\/bi012121x","volume":"41","author":"Cotton J.","year":"2002","unstructured":"Cotton J.; Hayashi M.A.F.; Cuniasse P.; Vazeux G.; Ianzer D.; De Camargo A.C.M.; Dive V.; Selective inhibition of the C domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry 2002,41(19),6065-6071","journal-title":"Biochemistry"},{"key":"ref=26","first-page":"1165","volume":"20","author":"Bonnet D.","year":"1992","unstructured":"Bonnet D.; Lemoine F.M.; Khoury E.; Pradelles P.; Najman A.; Guigon M.; Reversible inhibitory effects and absence of toxicity of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in human long-term bone marrow culture. Exp Hematol 1992,20(10),1165-1169","journal-title":"Exp Hematol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"H1226","DOI":"10.1152\/ajpheart.00305.2007","volume":"294","author":"Sharma U.","year":"2008","unstructured":"Sharma U.; Rhaleb N-E.; Pokharel S.; Harding P.; Rasoul S.; Peng H.; Carretero O.A.; Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 2008,294(3),H1226-H1232","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1042\/CS20090234","volume":"118","author":"Castoldi G.","year":"2009","unstructured":"Castoldi G.; di Gioia C.R.T.; Bombardi C.; Perego C.; Perego L.; Mancini M.; Leopizzi M.; Corradi B.; Perlini S.; Zerbini G.; Stella A.; Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clin Sci (Lond) 2009,118(3),211-220","journal-title":"Clin Sci (Lond)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","volume":"296","author":"Liu Y-H.","year":"2009","unstructured":"Liu Y-H.; D\u2019Ambrosio M.; Liao T.D.; Peng H.; Rhaleb N-E.; Sharma U.; Andr\u00e9 S.; Gabius H-J.; Carretero O.A.; N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth regulatory lectin. Am J Physiol Heart Circ Physiol 2009,296(2),H404-H412","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1161\/01.HYP.0000258406.66954.4f","volume":"49","author":"Peng H.","year":"2007","unstructured":"Peng H.; Carretero O.A.; Liao T-D.; Peterson E.L.; Rhaleb N-E.; Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension. Hypertension 2007,49(3),695-703","journal-title":"Hypertension"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"15946","DOI":"10.1074\/jbc.M400149200","volume":"279","author":"Fuchs S.","year":"2004","unstructured":"Fuchs S.; Xiao H.D.; Cole J.M.; Adams J.W.; Frenzel K.; Michaud A.; Zhao H.; Keshelava G.; Capecchi M.R.; Corvol P.; Bernstein K.E.; Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 2004,279(16),15946-15953","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd1227","volume":"2","author":"Acharya K.R.","year":"2003","unstructured":"Acharya K.R.; Sturrock E.D.; Riordan J.F.; Ehlers M.R.W.; Ace revisited: A new target for structure-based drug design. Nat Rev Drug Discov 2003,2(11),891-902","journal-title":"Nat Rev Drug Discov"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1073\/pnas.96.8.4330","volume":"96","author":"Dive V.","year":"1999","unstructured":"Dive V.; Cotton J.; Yiotakis A.; Michaud A.; Vassiliou S.; Jiracek J.; Vazeux G.; Chauvet M.T.; Cuniasse P.; Corvol P.; RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci USA 1999,96(8),4330-4335","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1021\/bi049504q","volume":"43","author":"Georgiadis D.","year":"2004","unstructured":"Georgiadis D.; Cuniasse P.; Cotton J.; Yiotakis A.; Dive V.; Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry 2004,43(25),8048-8054","journal-title":"Biochemistry"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"35685","DOI":"10.1074\/jbc.M110.167866","volume":"285","author":"Anthony C.S.","year":"2010","unstructured":"Anthony C.S.; Corradi H.R.; Schwager S.L.U.; Redelinghuys P.; Georgiadis D.; Dive V.; Acharya K.R.; Sturrock E.D.; The N domain of human angiotensin-I-converting enzyme: The role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407. J Biol Chem 2010,285(46),35685-35693","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nature01370","volume":"421","author":"Natesh R.","year":"2003","unstructured":"Natesh R.; Schwager S.L.U.; Sturrock E.D.; Acharya K.R.; Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003,421(6922),551-554","journal-title":"Nature"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"8718","DOI":"10.1021\/bi049480n","volume":"43","author":"Natesh R.","year":"2004","unstructured":"Natesh R.; Schwager S.L.U.; Evans H.R.; Sturrock E.D.; Acharya K.R.; Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I converting enzyme. Biochemistry 2004,43(27),8718-8724","journal-title":"Biochemistry"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jmb.2006.01.048","volume":"357","author":"Corradi H.R.","year":"2006","unstructured":"Corradi H.R.; Schwager S.L.U.; Nchinda A.T.; Sturrock E.D.; Acharya K.R.; Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol 2006,357(3),964-974","journal-title":"J Mol Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0165-6147(03)00196-2","volume":"24","author":"Brew K.","year":"2003","unstructured":"Brew K.; Structure of human ACE gives new insights into inhibitor binding and design. Trends Pharmacol Sci 2003,24(8),391-394","journal-title":"Trends Pharmacol Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10822-005-9017-z","volume":"19","author":"Kuster D.J.","year":"2005","unstructured":"Kuster D.J.; Marshall G.R.; Validated ligand mapping of ACE active site. J Comput Aided Mol Des 2005,19(8),609-615","journal-title":"J Comput Aided Mol Des"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00894-009-0500-7","volume":"15","author":"Rao N.K.","year":"2009","unstructured":"Rao N.K.; Yadav A.; Kumar Singh S.; An ab initio quantum mechanical drug designing procedure: Application to the design of balanced dual ACE\/NEP inhibitors. J Mol Model 2009,15(12),1447-1462","journal-title":"J Mol Model"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1021\/ci9005047","volume":"50","author":"Dimitropoulos N.","year":"2010","unstructured":"Dimitropoulos N.; Papakyriakou A.; Dalkas G.A.; Sturrock E.D.; Spyroulias G.A.; A computational approach to the study of the binding mode of dual ACE\/NEP inhibitors. J Chem Inf Model 2010,50(3),388-396","journal-title":"J Chem Inf Model"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00894-010-0862-x","volume":"17","author":"Wang X.","year":"2011","unstructured":"Wang X.; Wang J.; Lin Y.; Ding Y.; Wang Y.; Cheng X.; Lin Z.; QSAR study on angiotensin-converting enzyme inhibitor oligopeptides based on a novel set of sequence information descriptors. J Mol Model 2011,17(7),1599-1606","journal-title":"J Mol Model"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1021\/ci200083f","volume":"51","author":"Wang X.","year":"2011","unstructured":"Wang X.; Wu S.; Xu D.; Xie D.; Guo H.; Inhibitor and substrate binding by angiotensin-converting enzyme: Quantum mechanical\/molecular mechanical molecular dynamics studies. J Chem Inf Model 2011,51(5),1074-1082","journal-title":"J Chem Inf Model"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jmgm.2014.08.002","volume":"53","author":"Hai-Bang T.","year":"2014","unstructured":"Hai-Bang T.; Shimizu K.; Potent angiotensin-converting enzyme inhibitory tripeptides identified by a computer-based approach. J Mol Graph Model 2014,53,206-211","journal-title":"J Mol Graph Model"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1016\/j.bmcl.2017.07.016","volume":"27","author":"Ke Z.","year":"2017","unstructured":"Ke Z.; Su Z.; Zhang X.; Cao Z.; Ding Y.; Cao L.; Ding G.; Wang Z.; Liu H.; Xiao W.; Discovery of a potent angiotensin converting enzyme inhibitor via virtual screening. Bioorg Med Chem Lett 2017,27(16),3688-3692","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.compbiolchem.2018.10.001","volume":"77","author":"Panyayai T.","year":"2018","unstructured":"Panyayai T.; Sangsawad P.; Pacharawongsakda E.; Sawatdichaikul O.; Tongsima S.; Choowongkomon K.; The potential peptides against angiotensin-I converting enzyme through a virtual tripeptide-constructing library. Comput Biol Chem 2018,77,207-213","journal-title":"Comput Biol Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1042\/CS20130403","volume":"126","author":"Douglas R.G.","year":"2014","unstructured":"Douglas R.G.; Sharma R.K.; Masuyer G.; Lubbe L.; Zamora I.; Acharya K.R.; Chibale K.; Sturrock E.D.; Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. Clin Sci (Lond) 2014,126(4),305-313","journal-title":"Clin Sci (Lond)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1021\/jm061259g","volume":"50","author":"Bergmann R.","year":"2007","unstructured":"Bergmann R.; Linusson A.; Zamora I.; SHOP: Scaffold HOPping by GRID-based similarity searches. J Med Chem 2007,50(11),2708-2717","journal-title":"J Med Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1021\/ci800391v","volume":"49","author":"Bergmann R.","year":"2009","unstructured":"Bergmann R.; Liljefors T.; S\u00f8rensen M.D.; Zamora I.; SHOP: Receptor-based scaffold HOPping by GRID-based similarity searches. J Chem Inf Model 2009,49(3),658-669","journal-title":"J Chem Inf Model"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1021\/acs.jmedchem.7b01478","volume":"61","author":"Fienberg S.","year":"2018","unstructured":"Fienberg S.; Cozier G.E.; Acharya K.R.; Chibale K.; Sturrock E.D.; The Design and Development of a Potent and Selective Novel Diprolyl Derivative That Binds to the N-Domain of Angiotensin-I Converting Enzyme. J Med Chem 2018,61(1),344-359","journal-title":"J Med Chem"},{"key":"ref=52","unstructured":"GOSTAR Drug Database and Clinical Candidate Database; Excelra Knowledge Solutions: Hyderabad, India, Jul 22, 2013."},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0009-9236(98)90075-3","volume":"64","author":"Wallis E.J.","year":"1998","unstructured":"Wallis E.J.; Ramsay L.E.; Hettiarachchi J.; Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 1998,64(4),439-449","journal-title":"Clin Pharmacol Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0731-7085(97)00126-X","volume":"16","author":"Venn R.F.","year":"1998","unstructured":"Venn R.F.; Kaye B.; Macrae P.V.; Saunders K.C.; Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: Assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol. J Pharm Biomed Anal 1998,16(5),875-881","journal-title":"J Pharm Biomed Anal"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0731-7085(97)00127-1","volume":"16","author":"Venn R.F.","year":"1998","unstructured":"Venn R.F.; Barnard G.; Kaye B.; Macrae P.V.; Saunders K.C.; Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: Assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA). J Pharm Biomed Anal 1998,16(5),883-892","journal-title":"J Pharm Biomed Anal"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1021\/acs.jcim.6b00524","volume":"56","author":"Sharma R.K.","year":"2016","unstructured":"Sharma R.K.; Espinoza-Moraga M.; Poblete H.; Douglas R.G.; Sturrock E.D.; Caballero J.; Chibale K.; The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme. J Chem Inf Model 2016,56(12),2486-2494","journal-title":"J Chem Inf Model"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/febs.14421","volume":"285","author":"Cozier G.E.","year":"2018","unstructured":"Cozier G.E.; Schwager S.L.; Sharma R.K.; Chibale K.; Sturrock E.D.; Acharya K.R.; Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity. FEBS J 2018,285(8),1477-1490","journal-title":"FEBS J"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0149-2918(03)80107-8","volume":"25","author":"Guay D.R.P.","year":"2003","unstructured":"Guay D.R.P.; Trandolapril: A newer angiotensin-converting enzyme inhibitor. Clin Ther 2003,25(3),713-775","journal-title":"Clin Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2165\/00003495-199448010-00007","volume":"48","author":"Wiseman L.R.","year":"1994","unstructured":"Wiseman L.R.; McTavish D.; Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994,48(1),71-90","journal-title":"Drugs"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/0002-8703(93)90450-N","volume":"125","author":"Conen H.","year":"1993","unstructured":"Conen H.; Brunner H.R.; Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. Am Heart J 1993,125(5 Pt 2),1525-1531","journal-title":"Am Heart J"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.clinthera.2007.02.016","volume":"29","author":"Tytus R.H.","year":"2007","unstructured":"Tytus R.H.; Burgess E.D.; Assouline L.; Vanjaka A.; A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL). Clin Ther 2007,29(2),305-315","journal-title":"Clin Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1021\/jm030543u","volume":"47","author":"Pierce A.C.","year":"2004","unstructured":"Pierce A.C.; Rao G.; Bemis G.W.; BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. J Med Chem 2004,47(11),2768-2775","journal-title":"J Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/BF00125322","volume":"7","author":"Ho C.M.W.","year":"1993","unstructured":"Ho C.M.W.; Marshall G.R.; SPLICE: A program to assemble partial query solutions from Three-Dimensional Database Searches into novel ligands. J Comput Aided Mol Des 1993,7,623-647","journal-title":"J Comput Aided Mol Des"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"Friesner R.A.","year":"2004","unstructured":"Friesner R.A.; Banks J.L.; Murphy R.B.; Halgren T.A.; Klicic J.J.; Mainz D.T.; Repasky M.P.; Knoll E.H.; Shelley M.; Perry J.K.; Shaw D.E.; Francis P.; Shenkin P.S.; Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004,47(7),1739-1749","journal-title":"J Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"Friesner R.A.","year":"2006","unstructured":"Friesner R.A.; Murphy R.B.; Repasky M.P.; Frye L.L.; Greenwood J.R.; Halgren T.A.; Sanschagrin P.C.; Mainz D.T.; Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006,49(21),6177-6196","journal-title":"J Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1160\/TH13-05-0386","volume":"111","author":"Fuentes E.","year":"2014","unstructured":"Fuentes E.; Badimon L.; Caballero J.; Padr\u00f3 T.; Vilahur G.; Alarc\u00f3n M.; P\u00e9rez P.; Palomo I.; Protective mechanisms of adenosine 5\u2032-monophosphate in platelet activation and thrombus formation. Thromb Haemost 2014,111(3),491-507","journal-title":"Thromb Haemost"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112741","volume":"9","author":"Fuentes E.","year":"2014","unstructured":"Fuentes E.; Pereira J.; Mezzano D.; Alarc\u00f3n M.; Caballero J.; Palomo I.; Inhibition of platelet activation and thrombus formation by adenosine and inosine: Studies on their relative contribution and molecular modeling. PLoS One 2014,9(11)","journal-title":"PLoS One"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090699","volume":"9","author":"Fuentes E.","year":"2014","unstructured":"Fuentes E.; Caballero J.; Alarc\u00f3n M.; Rojas A.; Palomo I.; Chlorogenic acid inhibits human platelet activation and thrombus formation. PLoS One 2014,9(3)","journal-title":"PLoS One"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102212","volume":"9","author":"Quesada-Romero L.","year":"2014","unstructured":"Quesada-Romero L.; Mena-Ulecia K.; Tiznado W.; Caballero J.; Insights into the interactions between maleimide derivates and GSK3\u03b2 combining molecular docking and QSAR. PLoS One 2014,9(7)","journal-title":"PLoS One"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.1109\/SC.2006.54","volume":"84","author":"Bowers K.J.","year":"2006","unstructured":"Bowers K.J.; Chow E.; Xu H.; Dror R.O.; Eastwood M.P.; Gregersen B.A.; Klepeis J.L.; Kolossvary I.; Moraes M.A.; Sacerdoti F.D.; Salmon J.K.; Shan Y.; Shaw D.E.; Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters Proceedings of the Proceedings of the 2006 ACM\/IEEE conference on Supercomputing 2006,84","journal-title":"Proceedings of the Proceedings of the 2006 ACM\/IEEE conference on Supercomputing"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1021\/jp003919d","volume":"105","author":"Kaminski G.A.","year":"2001","unstructured":"Kaminski G.A.; Friesner R.A.; Tirado-Rives J.; Jorgensen W.L.; Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001,105,6474-6487","journal-title":"J Phys Chem B"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"14047","DOI":"10.1039\/C4CP01378F","volume":"16","author":"Adasme-Carre\u00f1o F.","year":"2014","unstructured":"Adasme-Carre\u00f1o F.; Mu\u00f1oz-Gutierrez C.; Caballero J.; Alzate-Morales J.H.; Performance of the MM\/GBSA scoring using a binding site hydrogen bond network-based frame selection: The protein kinase case. Phys Chem Chem Phys 2014,16(27),14047-14058","journal-title":"Phys Chem Chem Phys"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1021\/ct6003406","volume":"3","author":"Lee M.R.","year":"2007","unstructured":"Lee M.R.; Sun Y.; Improving docking accuracy through molecular mechanics generalized born optimization and scoring. J Chem Theory Comput 2007,3(3),1106-1119","journal-title":"J Chem Theory Comput"},{"key":"ref=74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109639","volume":"9","author":"Mena-Ulecia K.","year":"2014","unstructured":"Mena-Ulecia K.; Vergara-Jaque A.; Poblete H.; Tiznado W.; Caballero J.; Study of the affinity between the protein kinase PKA and peptide substrates derived from kemptide using molecular dynamics simulations and MM\/GBSA. PLoS One 2014,9(10)","journal-title":"PLoS One"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/ijms17040525","volume":"17","author":"Ram\u00edrez D.","year":"2016","unstructured":"Ram\u00edrez D.; Caballero J.; Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target? Int J Mol Sci 2016,17(4),525","journal-title":"Int J Mol Sci"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/177753\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/177753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T11:01:19Z","timestamp":1608202879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177753\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":75,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,9,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557520666191224113830","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}